Topical composition for treating diabetic cataracts: a patent evaluation (WO2015026380A1).
Diabetes mellitus is a major threat to global public health that requires long-term medical attention. In view of the potentially devastating effects of diabetes on ocular health, it highlights the urgent need of therapeutic drugs for the prevention and treatment of the diabetic complications. The patent described in this evaluation (WO2015026380A1) claimed a topical composition for treating diabetic cataracts both in animals and human beings. The composition containing a therapeutic amount of the 2R-methyl sorbinil, one of aldose reductase inhibitors, delivered to the dog's eye can exert a preventive, inhibitory, or prophylactic effect on diabetic cataracts in a statistically significant portion of the population being studied. Thus methods and strategies using new formulations of known inhibitors are promising for future use in the treatment of diabetic complications.